Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-16
1998-07-28
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
057863628
ABSTRACT:
Activation of the c-fos promoter and the serum response element (SRE) in androgen independent cancer cells has been demonstrated. In androgen dependent cells, direct activation of protein kinase C (PKC) or serum response factor (SRF) activated the c-fos promoter or SRE and caused androgen independent expression of an androgen target promoter. The highly specific PKC inhibitor chelerythrine selectively killed androgen independent cells. Expression of mutant SRF cDNA's inhibited activation of the SRE in prostate cancer cells. These reagents demonstrate the feasibility of both chemotherapy and gene therapy in interfering with intracellular pathways on which androgen independent cells are dependent; i.e. a strategy is outlined for treating hormone independent cancer in which the PKC-SRE pathway is disrupted by either chemotherapy or gene therapy.
REFERENCES:
Herbert et al., Biochem. Biophys. Res. Commun. vol. 172, No. 3, 1990, pp. 993-999.
Goldberg Jerome D.
University of Miami
LandOfFree
Method of treating Hormone independent cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating Hormone independent cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating Hormone independent cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-23869